TABLE 2

MSC therapy in various disease models in animals

OutcomesReference
STZ diabetesHuman-MSC grafted kidney and pancreas in STZ NOD.SCID mice ameliorating diabetes and kidney disease59
Heart transplantationAllogenic rat-MSCs injected intravenously migrated to the heart during chronic rejection60
Heart transplantationAllogenic rat-MSCs co-injected with cyclosporine accelerate rejection50
Myocardial infarctionSyngeneic rat-MSCs showed an anti-inflammation role in ischemic heart disease61
Acute lung injurySyngeneic intrapulmonary murine-MSCs decrease the severity of endotoxin-induced acute lung injury and improve survival in mice62
Chronic lung injurySyngeneic murine-MSCs protect lung tissue from bleomycin-induced injury with anti-inflammatory effect63
ArthritisAllogenic murine-MSCs reduce joint inflammation and increase Treg generation44
Kidney ischemia reperfusion injurySyngeneic murine-MSCs are helpful in the restoration of tubular epithelial cells with an anti-inflammatory effect42
Multiple sclerosis model (EAE)Syngeneic murine-MSCs are home to inflamed lymphoid tissues reducing disease progression43,64
Acute hepatic failureHuman-MSCs protect against hepatocyte death and increase survival in mice after the injections of the hepatotoxin D-galactosamine65
GHVDAllogenic rat-MSCs prevent lethal GVHD66
GVHDAllogenic murine-MSCs did not improve GVHD49
BM transplantationDonor-MSCs increase rejection of allogeneic donor bone marrow cells37
  • Italics indicate contrasting reports. MSC were all bone marrow–derived (BM-MSC). EAE, experimental autoimmune encephalomyelitis; STZ, streptozotocin.